<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04393584</url>
  </required_header>
  <id_info>
    <org_study_id>2019-01</org_study_id>
    <nct_id>NCT04393584</nct_id>
  </id_info>
  <brief_title>FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma</brief_title>
  <acronym>RusGCG-01</acronym>
  <official_title>Perioperative Chemotherapy With FOLFIRINOX Regimen or FLOT Regimen for Resectable Gastric or Esophagogastric Junction Adenocarcinoma (Type II-III): Open-label Randomized Phase 2/3 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blokhin's Russian Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blokhin's Russian Cancer Research Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with resectable adenocarcinoma of the stomach or the esophagogastric junction
      (II-III type by Siewert) without previous therapy will be treated with one of two
      chemotherapy combinations before and after surgery. One half of the patients gets
      5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Docetaxel (FLOT), the others
      5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Irinotecan (FOLFIRINOX). Main objective of
      the study is median overall survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      538 Patients with resectable (cT4cN0 or cT1-4 and cN+, cM0) adenocarcinoma of the stomach or
      the esophagogastric junction without previous therapy will be included in this study. After
      randomization patients receive perioperatively 4 cycles FLOT or FOLFIRINOX, followed by a
      restaging of the tumour status and surgery. Subsequently another 4 cycles of FLOT or
      FOLFIRNOX are applicated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 30, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>median overall survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathologic complete response rate</measure>
    <time_frame>1 month after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative Morbidity and Mortality</measure>
    <time_frame>1 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0-Resection rate</measure>
    <time_frame>1 month after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">538</enrollment>
  <condition>Stomach Neoplasms</condition>
  <condition>Gastrointestinal Neoplasms</condition>
  <condition>Docetaxel</condition>
  <condition>Oxaliplatin</condition>
  <condition>Fluoruracil</condition>
  <condition>Irinotecan Hydrochloride</condition>
  <arm_group>
    <arm_group_label>FOLFIRINOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan 180mg/m2 d1, d1-2 5-FU 2450 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (4-8 weeks) pre-OP and 4 cycles (6-12 weeks) post-OP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FLOT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>d1 Docetaxel 50mg/m2, d1-2 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m² every two weeks (q2w) 4 cycles (4-8 weeks) pre-OP and 4 cycles (6-12 weeks) post-OP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>d1 Irinotecan 180mg/m² every two weeks</description>
    <arm_group_label>FOLFIRINOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>d1-2 5-FU 2450 mg/m² every two weeks</description>
    <arm_group_label>FLOT</arm_group_label>
    <arm_group_label>FOLFIRINOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>d1 Leucovorin 200 mg/m² every two weeks</description>
    <arm_group_label>FLOT</arm_group_label>
    <arm_group_label>FOLFIRINOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>d1 Oxaliplatin 85 mg/m² every two weeks</description>
    <arm_group_label>FLOT</arm_group_label>
    <arm_group_label>FOLFIRINOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>d1 Docetaxel 50mg/m2 every two weeks</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. сT4 cN0 or cT1-4 cN+ histologically proven adenocarcinoma of the esophagogastric
             junction (Siewert type II-III) or the stomach without distant metastases (M0)

          2. No previous cytostatic chemotherapy or radiation therapy

          3. Age 18-70 years (female and male)

          4. Eastern Cooperative Oncology Group ≤ 2

          5. Surgical resectability

          6. Neutrophils&gt; 2.000/µl

          7. Platelets &gt; 100.000/µl

          8. Normal value of Serum Creatinin

          9. Albumin level &gt; 29 г/л

         10. Aspartate transaminase (AST) or alanine transaminase (ALT) less than 3 times the upper
             limits of normal (ULN)

         11. Total Bilirubin less than 1.5 times the ULN

         12. Written informed consent.

        Exclusion Criteria:

          1. Previous cytostatic chemotherapy or radiation therapy

          2. Distant metastases or all primarily not resectable stages

          3. Cancer relapse

          4. Complicated gastric cancer (perforation, bleeding, sub or decompensated stenosis,
             dysphagia IV)

          5. Diarrhea ≥ 2 according to the criteria of Common Terminology Criteria for Adverse
             Events (CTCAE) version 4.1;

          6. Hypersensitivity against 5- Fluorouracil, Leucovorin, Oxaliplatin, Epirubicin and
             Docetaxel

          7. Existence of contraindications against 5- Fluorouracil, Leucovorin, Oxaliplatin,
             Irinotecan or Docetaxel

          8. Active coronary heart disease, Cardiomyopathy or cardiac insufficiency stage III-IV
             according to New York Heart Association (NYHA)

          9. Severe non-surgical accompanying disease or acute infection (uncontrolled arterial
             hypertension, diabetes mellitus, stroke less than 6 months old, mental disorders,
             other tumors and others)

         10. Malignant secondary disease, dated back &lt; 5 years (exception: In-situ-carcinoma of the
             cervix uteri, adequately treated skin basal cell carcinoma)

         11. Peripheral polyneuropathy &gt; Grad II

         12. Liver dysfunction (AST)/ALT&gt;3,0xULN, ALT&gt;3xULN, Bilirubin&gt;1,5xULN)

         13. Serum Creatinin &gt;1,0xULN

         14. Chronic inflammable gastro-intestinal disease

         15. Inclusion in another clinical trial

         16. Pregnancy or lactation

         17. Hepatitis B or C in the active stage

         18. Human immunodeficiency virus(HIV) infected

         19. Serious concomitant somatic and mental illnesses / deviations or territorial causes
             that may prevent the patient from participating in the protocol and observing the
             protocol schedule

         20. Foreigners or persons with limited legal status
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan Stilidi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NN Blokhin National Medical Research Center of Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aleksei Kalinin, Phd</last_name>
    <phone>+79197681276</phone>
    <email>kalininalexey1986@yandex.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sergey Nered, Phd</last_name>
    <phone>+79031995078</phone>
    <email>nered@mail.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aleksei Kalinin</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksei Kalinin</last_name>
      <phone>+79197681276</phone>
      <email>kalininalexey1986@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Ivan Stilidi, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergey Nered, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aleksei Kalinin, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natalya Besova, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>May 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 17, 2020</last_update_submitted>
  <last_update_submitted_qc>May 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>pathological complete</keyword>
  <keyword>FLOT</keyword>
  <keyword>FOLFIRINOX</keyword>
  <keyword>gastrectomy</keyword>
  <keyword>adenocarcinoma of the esophagogastric junction</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

